Breast Cancer Now media statements
We respond to the announcement of more than £25m being invested in diagnostic equipment for NHS Wales
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, said:
We respond to government funding announcement for early career researchers supported by charities
Responding to the Department for Business, Energy and Industrial Strategy's (BEIS) announcement of funding for early career researchers supp...
We respond to a new clinical trial into olaparib use for women with high risk HER2 negative primary breast cancer with altered BRCA genes
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to new research into fertility drugs and breast cancer risk
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: May 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to ‘plasmaMATCH’ trial that uses blood test to match women with breast cancer to a range of precision treatments
The plasmaMATCH trial investigates whether simple blood tests known as ‘liquid biopsies’ can benefit women with breast cancer, by tracking t...
We support recommendations for faster and wider access to innovative cancer treatments
Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, said:
We respond to news that the pandemic ‘threatens research as early career scientists look to leave’
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said,
We respond to a BMJ Study that provides new estimates of breast cancer risks associated with HRT
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said: